OBJECTIVE: To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling. DESIGN: Cross-sectional observational study. SETTING: Thirteen movement disorders centers. PATIENTS: Nine hundred fifty-three individuals with early-onset PD defined as age at onset (AAO) younger than 51 years. Participants included 77 and 139 individuals of Hispanic and Jewish ancestry, respectively. Intervention Mutations in SNCA, PRKN, PINK1, DJ1, LRRK2, and GBA were assessed. A validated family history interview and the Unified Parkinson Disease Rating Scale were administered. Demographic and phenotypic characteristics were compared among groups defined by mutation status. Main Outcome Measure Mutation carrier frequency stratified by AAO and ethnic background. RESULTS: One hundred fifty-eight (16.6%) participants had mutations, including 64 (6.7%) PRKN, 35 (3.6%) LRRK2 G2019S, 64 (6.7%) GBA, and 1 (0.2%) DJ1. Mutation carriers were more frequent in those with an AAO of 30 years or younger compared with those with AAO between 31 and 50 years (40.6% vs 14.6%, P < .001), in individuals who reported Jewish ancestry (32.4% vs 13.7%, P < .001), and in those reporting a first-degree family history of PD (23.9% vs 15.1%, P = .01). Hispanic individuals were more likely to be PRKN carriers than non-Hispanic individuals (15.6% vs 5.9%, P = .003). The GBA L444P mutation was associated with a higher mean Unified Parkinson Disease Rating Scale III score after adjustment for covariates. CONCLUSION: Individuals of Jewish or Hispanic ancestry with early-onset PD, those with AAO of 30 years or younger, and those with a history of PD in a first-degree relative may benefit from genetic counseling.
OBJECTIVE: To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling. DESIGN: Cross-sectional observational study. SETTING: Thirteen movement disorders centers. PATIENTS: Nine hundred fifty-three individuals with early-onset PD defined as age at onset (AAO) younger than 51 years. Participants included 77 and 139 individuals of Hispanic and Jewish ancestry, respectively. Intervention Mutations in SNCA, PRKN, PINK1, DJ1, LRRK2, and GBA were assessed. A validated family history interview and the Unified Parkinson Disease Rating Scale were administered. Demographic and phenotypic characteristics were compared among groups defined by mutation status. Main Outcome Measure Mutation carrier frequency stratified by AAO and ethnic background. RESULTS: One hundred fifty-eight (16.6%) participants had mutations, including 64 (6.7%) PRKN, 35 (3.6%) LRRK2G2019S, 64 (6.7%) GBA, and 1 (0.2%) DJ1. Mutation carriers were more frequent in those with an AAO of 30 years or younger compared with those with AAO between 31 and 50 years (40.6% vs 14.6%, P < .001), in individuals who reported Jewish ancestry (32.4% vs 13.7%, P < .001), and in those reporting a first-degree family history of PD (23.9% vs 15.1%, P = .01). Hispanic individuals were more likely to be PRKN carriers than non-Hispanic individuals (15.6% vs 5.9%, P = .003). The GBAL444P mutation was associated with a higher mean Unified Parkinson Disease Rating Scale III score after adjustment for covariates. CONCLUSION: Individuals of Jewish or Hispanic ancestry with early-onset PD, those with AAO of 30 years or younger, and those with a history of PD in a first-degree relative may benefit from genetic counseling.
Authors: Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman Journal: N Engl J Med Date: 2006-01-26 Impact factor: 91.245
Authors: E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner Journal: Neurology Date: 2006-11-02 Impact factor: 9.910
Authors: L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder Journal: Neurology Date: 2007-09-18 Impact factor: 9.910
Authors: Lorraine N Clark; Shehla Afridi; Helen Mejia-Santana; Juliette Harris; Elan D Louis; Lucien J Cote; Howard Andrews; Andrew Singleton; Fabienne Wavrant De-Vrieze; John Hardy; Richard Mayeux; Stanley Fahn; Cheryl Waters; Blair Ford; Steven Frucht; Ruth Ottman; Karen Marder Journal: Mov Disord Date: 2004-07 Impact factor: 10.338
Authors: George D Mellick; Gerhard A Siebert; Manabu Funayama; Daniel D Buchanan; Yuanzhe Li; Yoko Imamichi; Hiroyo Yoshino; Peter A Silburn; Nobutaka Hattori Journal: Parkinsonism Relat Disord Date: 2008-05-19 Impact factor: 4.891
Authors: Sarah Teixeira Camargos; Leonardo Oliveira Dornas; Parastoo Momeni; Andrew Lees; John Hardy; Andrew Singleton; Francisco Cardoso Journal: Mov Disord Date: 2009-04-15 Impact factor: 10.338
Authors: R N Alcalay; E Caccappolo; H Mejia-Santana; M -X Tang; L Rosado; M Orbe Reilly; D Ruiz; B Ross; M Verbitsky; S Kisselev; E Louis; C Comella; A Colcher; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; H Andrews; C Waters; S Fahn; L Cote; S Frucht; B Ford; M Rezak; K Novak; J H Friedman; R Pfeiffer; L Marsh; B Hiner; A Siderowf; H Payami; E Molho; S Factor; R Ottman; L N Clark; K Marder Journal: Neurology Date: 2012-03-21 Impact factor: 9.910
Authors: Rachel C Harris; Jessica I Lundin; Susan R Criswell; Angela Hobson; Laura M Swisher; Bradley A Evanoff; Harvey Checkoway; Brad A Racette Journal: Parkinsonism Relat Disord Date: 2011-07-02 Impact factor: 4.891
Authors: Nancy J Butcher; Tim-Rasmus Kiehl; Lili-Naz Hazrati; Eva W C Chow; Ekaterina Rogaeva; Anthony E Lang; Anne S Bassett Journal: JAMA Neurol Date: 2013-11 Impact factor: 18.302